#AS­CO17 high­lights: Roche ush­ers ear­ly-stage bis­pe­cif­ic in­to view; Agios, Cel­gene un­veil more AG-221 da­ta; Plen­ty more com­ing at AS­CO

Roche has an ear­ly-stage T cell bis­pe­cif­ic — which binds si­mul­ta­ne­ous­ly to T cells and tu­mor cells — called CEA-TCB (RO6958688; RG7802) that it is bull­ish about. It re­leased a very ear­ly look at Phase I da­ta for AS­CO, look­ing at monother­a­py as well as a com­bo with its check­point Tecen­triq. The da­ta demon­strate: “In the monother­a­py, out of 31 pa­tients with mCRC treat­ed with CEA-TCB dos­es of 60mg or above, 14 pa­tients (45%) showed ei­ther par­tial re­sponse (n=2, 6%) or sta­ble dis­ease (n=12, 39%). For the com­bi­na­tion, of 25 pa­tients treat­ed with dos­es of 5–160mg of CEA-TCB, 11 pa­tients with MSS mCRC were treat­ed at dos­es shown to in­duce tu­mour le­sion in­flam­ma­tion (80 and 160 mg). Nine of these pa­tients (82%) showed ei­ther a par­tial re­sponse (n=2, 18%) or sta­ble dis­ease (n=7, 64%) in this dif­fi­cult-to-treat pop­u­la­tion.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER